In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on AC Immune SA (ACIU), with a price target of $18. The company’s shares closed yesterday at $11.10.
Fein commented:
“Our 12-month price target of $18/share is based on an equally weighted composite of (a) $19/share, as a 35x multiple of taxed and diluted FY27 GAAP EPS of $2.82 discounted back to and (b) an NPV of $17/share (discount rate 11.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.1% and a 42.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $18.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.40 and a one-year low of $7.16. Currently, AC Immune SA has an average volume of 127.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
